Observational studyItalian journal of pediatrics2026
Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study.
Observational study in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiolitis is the leading cause of lower respiratory tract infections in infants, with respiratory syncytial virus (RSV) as the primary pathogen. Nirsevimab, a long-acting monoclonal antibody, was introduced in Europe in late 2022 for RSV prophylaxis in all infants. In Italy, the 2024–2025 immunization campaign faced regional disparities in implementation. This study aimed to evaluate the impact of Nirsevimab in reducing bronchiolitis diagnoses and hospitalizations in infants during their first RSV season in the Lazio Region.
methodsWe conducted a retrospective cohort study using data from 29 primary care pediatricians in Lazio. Infants born between August 17, 2024, and March 31, 2025, were included. Bronchiolitis diagnoses were clinically defined, and immunization status was obtained from the regional vaccination registry. We excluded premature infants (< 33 weeks) and those diagnosed before the immunization campaign began on December 9, 2024. To adjust for confounding, we applied inverse probability weighting (IPW) based on a propensity score including demographic and clinical covariates. A negative binomial mixed-effects model was used to estimate incidence rate ratios (IRRs) for bronchiolitis and hospitalizations.
resultsAmong 818 eligible infants, 613 (74.9%) were immunized. A total of 58 bronchiolitis cases were recorded (7.1%), with 6.5% in the immunized group and 8.8% in the non-immunized group. Crude analysis showed a 25.7% risk reduction, while IPW-adjusted analysis indicated a 50.4% reduction (95% CI: 44.4%–55.7%). Hospitalizations occurred in 2.0% of infants, with adjusted analysis showing a 49.1% reduction in hospitalization risk among immunized infants. The immunization campaign’s late start likely limited its full impact, as 40 early-season cases were excluded.
conclusionsNirsevimab immunization significantly reduced the risk of bronchiolitis and related hospitalizations in a real-world primary care setting. This result aligns with previous studies, though it may be underestimated due to the delayed campaign start and inclusion of all-cause bronchiolitis. These findings support early and widespread implementation of Nirsevimab to optimize protection and reduce RSV burden in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.